Nurix Therapeutics Inc (NRIX) Stock Analysis
Verdict: HOLD
Strong BTK-degrader pipeline momentum and major pharma backing face a valuation ceiling and consistent insider selling near 52-week highs.
Investment score: 62/100
Analysis as of
Is Nurix Therapeutics Inc stock worth reviewing? AI model thesis
Clinical momentum is high but price is extended relative to peers and insider activity.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Nurix Therapeutics Inc opportunities and risks
What speaks for NRIX
- Strategic Validation by Tier-1 Partners
What speaks against NRIX
- Active Insider Liquidation Trend
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| NRIX | n/a | 53.7x | n/a | -155.0% | -928.4% | -15.4% |
| KLRA | n/a | 0.0x | n/a | 0.0% | 0.0% | -4.7% |
| IMNM | n/a | 538.2x | n/a | -1161.9% | -5593.8% | -9.5% |
| BCRX | n/a | 2.5x | n/a | 18.9% | -51.7% | 13.5% |
| MLYS | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.4% |
| AGIO | n/a | 36.5x | n/a | 82.1% | -639.8% | -15.9% |
| Peer median | n/a | 2.5x | n/a | 0.0% | -51.7% | -7.4% |
Frequently asked questions about Nurix Therapeutics Inc (NRIX)
Is NRIX stock a good investment?
The cached TradeMates AI model rates Nurix Therapeutics Inc as HOLD with an investment score of 62/100. Clinical momentum is high but price is extended relative to peers and insider activity. This is algorithmic model output, not personal investment advice.
Is NRIX stock a buy?
The TradeMates model verdict for NRIX is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.